Venture Capital Growth In Orphan Drugs Aided By ‘Regulatory Certainty’
Executive Summary
Investment funds seeking greater clarity around regulatory and reimbursement issues increasingly are turning away from chronic disease drug development in favor of new treatments for rare diseases, according to two studies.
You may also be interested in...
Venture Funding Continues Upward Climb, But On The Backs Of Fewer Investors – BIO Report
Oncology companies have been garnering the most investment from venture capital firms over the last 10 years due to their high levels of innovation, according to a new report from the industry group.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.
Puberty Blockers: FDA's Califf Asked If REMS, Boxed Warning Against Off-Label Use In The Works
FDA Commissioner Robert Califf tells House appropriations subcommittee chair the agency will 'consider any information that may be available' on off-label use of puberty blockers for gender dysphoria before making a regulatory decision.